ABBOTT INDIA LIMITED

Glooko, a digital platform for managing diabetes and chronic diseases, secured $100 million in Series F funding led by Georgian, with Canaan, Health Catalyst Capital, and others participating. Mike Alvarez, former CEO of Qardio, was appointed as Glooko's new CEO. The funds will be used to scale global product expansion. Glooko integrates with various partners to enhance its diabetes management platform.

Abbott achieved milestones in two PFA trials for AF treatment, with the VOLT-AF study enrolling ahead of schedule and the FOCALFLEX study underway. The VOLT PFA system showed positive results in a feasibility study, and Abbott's Advisor HD Grid X Mapping Catheter received FDA clearance. PFA, using short bursts of electrical energy, is seen as an advancement over thermal ablation.

Abbott completed enrollment in a global clinical trial of its Volt pulsed field ablation (PFA) system four months ahead of schedule, aiming to compete with Boston Scientific and Medtronic. The trial's primary endpoint is the rate of freedom from atrial fibrillation after 12 months. Abbott also received clearance for its Advisor HD Grid X Mapping Catheter and initiated a Tactiflex Duo Ablation Catheter trial. Analysts view PFA devices as a threat to Abbott's electrophysiology business, but CEO Robert Ford anticipates market entry for Abbott's PFA portfolio next year.

Barry Farber, a UM alumnus, bequeathed $5.4 million to Sylvester Comprehensive Cancer Center to support the construction of the Kenneth C. Griffin Cancer Research Building, set to open in 2025. His estate also included over $500,000 in immediate-use research funding for head and neck cancers, sarcomas, prostate cancer, and the Firefighter Cancer Initiative.

Abbott achieved milestones in PFA solutions: early VOLT-AF IDE Study enrollment and FOCALFLEX trial launch. FDA cleared Advisor HD Grid X Mapping Catheter. PFA uses electrical pulses instead of heat or cold for AFib treatment, aiming for safer ablation. Abbott's Volt PFA System and TactiFlex Duo Ablation Catheter, SE, address PFA limitations. Heart mapping remains crucial for effective ablation.

Abbott achieved milestones in electrophysiology with early VOLT-AF IDE study completion and FOCALFLEX trial launch for TactiFlex Duo ablation catheter. FDA cleared Advisor HD Grid X mapping catheter for PFA and RF ablation cases. Abbott's PFA systems aim to address limitations of early-generation systems, with VOLT-AF enrolling 400 patients four months ahead of schedule.

Abbott completes enrollment in VOLT-AF IDE Study for Volt™ PFA System and launches FOCALFLEX trial for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. FDA clears Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™ for advanced cardiac mapping.

U.S. roadside drug testing market size was USD 1.45 billion in 2023, expected to reach USD 2.28 billion by 2033, growing at a CAGR of 4.65%. Alcohol segment dominated with 31.96% share in 2023, while cannabis/marijuana segment is projected to grow at the highest CAGR of 5.50%. Breath segment led with 44.44% share in 2023, and highway police segment dominated with 90.87% share. Market growth attributed to rising drug use, legalization of marijuana, and increasing awareness of drug-impaired driving. California led with 14.58% revenue share in 2023, driven by large population and progressive drug regulations.

The Companion Diagnostics Market was valued at USD 7.66 Billion in 2023 and is projected to reach USD 21.15 Billion by 2032, growing at a CAGR of 11.9% due to increased demand for personalized medicine, particularly in oncology. Key players include Abbott, Guardant Health, and Thermo Fisher Scientific. North America dominates the market, with Europe experiencing rapid growth. Recent developments include Illumina's next-generation sequencing test and Roche's blood-based diagnostic.

CMS is considering national Medicare reimbursement for Abbott's Triclip device, used in transcatheter tricuspid valve repair (T-TEER), following a formal request. The review focuses on clinical indications, patient benefits, and treatment conditions. Public comments are sought, with a proposed decision memo due by April 2025.